Left ventricular phosphorylation patterns of Akt and ERK1/2 after triiodothyronine intracoronary perfusion in isolated hearts and short-term in vivo treatment in Wistar rats

سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 217

فایل این مقاله در 9 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-23-8_017

تاریخ نمایه سازی: 27 مرداد 1399

چکیده مقاله:

Objective(s): To determine the effects of triiodothyronine (T3) intracoronary perfusion in isolated hearts and short-term administration in rats on the left ventricular (LV) phosphorylation patterns of Akt and ERK1/2. Materials and Methods: Cardiodynamic and hemodynamic parameters were evaluated in Langendorff–perfused hearts. Left ventricles were used for histomorphometric and Western blot analyses. Short-term hyperthyroidism was established by T3 (500 μg.kg-1.d-1; subcutaneous injection) for 1 (T31d), 3 (T33d), and 10 (T310d) days. Results: Isolated hearts receiving T3 perfusion did not modify LV developed pressure, +dP/dtmax, -dP/dtmin, heart rate, and coronary perfusion pressure compared with vehicle-perfused hearts. P-ERK1/2 and p-Akt levels in LV tissues after 5, 15, or 60 min of T3 or vehicle perfusion were similar. Compared with their time-matched controls, isolated hearts of T33d and T310d rats exhibited LV hypertrophy and increased absolute values of +dP/dtmax and -dP/dtmin (i.e., positive inotropic and lusitropic effects). P-ERK1/2 decreased in LV tissues of T31d and T310d but not in those of T33d rats, and p-Akt levels augmented in left ventricles of T33d and stayed unaltered in those of T31d and T310d rats.Conclusion: T3 intracoronary perfusion did not alter cardiodynamics and hemodynamics nor influence the activation of Akt and ERK of normal hearts. Accordingly, the rapid non-genomic effects of T3 were not evident. Short-term T3 treatment provoked cardiac hypertrophy coincidental with increased LV function and associated with transient Akt activation and cyclic ERK1/2 inhibition; which implies activation of  physiological hypertrophy signaling and deactivation of  pathological hypertrophy signaling, respectively.

کلیدواژه ها:

Akt ERK1 ، 2 Heart hypertrophy Rat Triiodothyronine treatment

نویسندگان

Jose Morales

Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México

Ruth Lopez

Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México

Jorge Lopez

Departamento de Biología Celular, Instituto Nacional de Perinatología, Ciudad de México, México

Jair Lozano

Departamento de Biología Celular, Instituto Nacional de Perinatología, Ciudad de México, México

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of ...
  • Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. ...
  • Ojamaa K. Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy. Vascul ...
  • Luidens MK, Mousa SA, Davis FB, Lin HY, Davis PJ. ...
  • Davis PJ, Leonard JL, Davis FB. Mechanisms of nongenomic actions ...
  • Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid ...
  • Vella KR, Hollenberg AN. The actions of thyroid hormone signaling ...
  • Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail ...
  • Pingitore A, Nicolini G, Kusmic C, Iervasi G, Grigolini P, ...
  • Gerdes AM, Ojamaa K. Thyroid Hormone and Cardioprotection. Compr Physiol ...
  • Elnakish MT, Ahmed AA, Mohler PJ, Janssen PM. Role of ...
  • Kuzman JA, O’Connell TD, Gerdes AM. Rapamycin prevents thyroid hormone-induced ...
  • Suarez J, Scott BT, Suarez-Ramirez J, Chavira CV, Dillmann WH. ...
  • Pantos C, Mourouzis I, Saranteas T, Clavé G, Ligeret H, ...
  • Honda H, Iwata T, Mochizuki T, Kogo H. Changes in ...
  • Weltman NY, Ojamaa K, Savinova OV, Chen YF, Schlenker EH, ...
  • Tavares FM, da Silva IB, Gomes DA, Barreto-Chaves ML. Angiotensin ...
  • Ulm S, Liu W, Zi M, Tsui H, Chowdhury SK, ...
  • Skrzypiec-Spring M, Grotthus B, Szelag A, Schulz R. Isolated heart ...
  • Bell RM, Mocanu MM, Yellon DM. Retrograde heart perfusion: the ...
  • Liao R, Podesser BK, Lim CC. The continuing evolution of ...
  • López RM, Castillo MC, López JS, Guevara G, López P, ...
  • Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of ...
  • Segal J, Masalha S, Schwalb H, Merin G, Borman JB, ...
  • Yoneda K, Takasu N, Higa S, Oshiro C, Oshiro Y, ...
  • Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. ...
  • Iordanidou A, Hadzopoulou-Cladaras M, Lazou A. Non-genomic effects of thyroid ...
  • Pantos C, Xinaris C, Mourouzis I, Malliopoulou V, Kardami E, ...
  • Kenessey A, Ojamaa K. Thyroid hormone stimulates protein synthesis in ...
  • Dorn GW II. The fuzzy logic of physiological cardiac hypertrophy. ...
  • Kehat I, Molkentin JD. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling ...
  • McMullen JR, Jennings GL. Differences between pathological and physiological cardiac ...
  • Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction ...
  • Lorenz K, Schmitt JP, Vidal M, Lohse MJ. Cardiac hypertrophy: ...
  • Shiojima I, Walsh K. Regulation of cardiac growth and coronary ...
  • Degens H, Gilde AJ, Lindhout M, Willemsen PH, Van Der ...
  • Kuzman JA, Vogelsang KA, Thomas TA, Gerdes AM. L-Thyroxine activates ...
  • Araujo AS, Schenkel P, Enzveiler AT, Fernandes TR, Partata WA, ...
  • Araujo AS, Fernandes T, Ribeiro MF, Khaper N, Belló-Klein A. ...
  • Fernandes RO, Dreher GJ, Schenkel PC, Fernandes TR, Ribeiro MF, ...
  • نمایش کامل مراجع